Search
Sunday 31 January 2016
  • :
  • :

Active Movers to Watch: Wells Fargo & Company, (NYSE:WFC), Halcón Resources Corporation, (NYSE:HK), Synergy Pharmaceuticals, (NASDAQ:SGYP)

Active Movers to Watch: Wells Fargo & Company, (NYSE:WFC), Halcón Resources Corporation, (NYSE:HK), Synergy Pharmaceuticals, (NASDAQ:SGYP)

On Tuesday, Shares of Wells Fargo & Company (NYSE:WFC), gained 0.32% to $56.24.

Wells Fargo & Company, unveiled redesigned treasury administration applications, counting information reporting and fraud prevention, on its Commercial Electronic Office® (CEO®) portal. The enhancements speed up business customers’ access to their information and ability to get things done on any mobile device they choose, counting smartphones, tablets, or laptops.

The declaration coincided with the 15-year anniversary this month of the CEO portal, the banking industry’s first single sign-on point of access to a variety of financial services for businesses in 2000. Recently, Wells Fargo commercial, corporate, and institutional customers in more than 190 countries use the CEO portal to connect to 90-plus online banking services. Active CEO users have raised 120 percent in the last five years.

Wells Fargo & Company provides retail, commercial, and corporate banking services to individuals, businesses, and institutions. Its Community Banking segment offers checking, savings, market rate, individual retirement, and health savings accounts, in addition to time deposits and remittances; and lines of credit, auto floor plan lines, equity lines and loans, equipment and transportation loans, education and residential mortgage loans, and debit and credit cards.

Shares of Halcón Resources Corporation (NYSE:HK), declined -0.85% to $1.16, during its last trading session, despite U.S. oil prices rose on Tuesday, posting a 25% quarterly gain, after Iran and six world powers extended the deadline for nuclear talks until July 7.

Prices also rose on the expectation that weekly inventory data due Wednesday would show a ninth straight weekly decline in U.S. oil supplies, according to WSJ.

Light, sweet crude for August delivery settled up $1.14, or 2%, at $59.47 a barrel on the New York Mercantile Exchange. WSJ Reports.

Brent, the global benchmark, rose $1.58, or 2.5%, to $63.59 a barrel on ICE Futures Europe. The contract rose 15% in the second quarter, the biggest single-quarter percentage gain since the first quarter of 2011, but fell 3% in June. WSJ added.

Halcón Resources Corporation, an independent energy company, is engaged in the acquisition, production, exploration, and development of onshore oil and natural gas properties in the United States. The company primarily holds interests the Bakken/Three Forks Formations comprising about 129,000 net acres of area in North Dakota; and East Texas Eagle Ford Formations covering about 101,000 acres of area in Brazos, Burleson, and Robertson counties.

Finally, Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP), ended its last trade with 5.87% gain, and closed at $8.30.

Synergy Pharmaceuticals declared that it has designated Timothy Callahan and Richard Daly as new independent directors to its board. Both Mr. Callahan and Mr. Daly have direct experience in primary care and gastrointestinal markets and have led large organizational change and successful business growth, in a variety of areas, counting all aspects of commercial, acquisitions, partnerships and product launches.

“I am happy to welcome the addition of two superb individuals, Tim Callahan and Rich Daly, to our board during this period of noteworthy growth and evolution in our business,” said Gary S. Jacob, Ph.D., Chairman and CEO of Synergy, “Their appointments mark an important step in our efforts to put the right structure and exceptional leadership in place to provide the highest level of guidance and expertise for maximizing the value of plecanatide.”

Synergy Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development of drugs to treat gastrointestinal (GI) disorders and diseases. Its lead product candidate is plecanatide, a guanylyl cyclase C receptor agonist that is in Phase III clinical trials to treat chronic idiopathic constipation GI disorders; and for the treatment of constipation-predominant irritable bowel syndrome GI disorders.

DISCLAIMER:

This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.

All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.

Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.

Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.




Leave a Reply

Your email address will not be published. Required fields are marked *